But many people with substance use disorders wont accept methadone or buperenorphine treatment after becoming sober from opioids in prison, they are often reluctant to begin an opioid agonist therapy
Specific barriers to prescription and optimal use of GLP-1 RAs include AEs, particularly GI side effects, s.c
Subcutaneous injection bypasses all of these barriers except plasma half-life, which for unmodified small peptides is generally very short (minutes to low hours, based on class-level pharmacokinetic data for similar unmodified peptides)
As GLP-1s have moved towards weekly dosing, users are less likely to experience the desensitisation that comes from repeated exposure
To address these limitations, inorganic fluorescent nanoparticles such as inorganic quantum dots have been evaluated to label polymeric nanocarriers 9,10,11
You dont become fit forever after one month, right